NCT07482605 2026-03-20
Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
Jiangmen Central Hospital
Phase 2 Not yet recruiting
Clinical Trials
3 trialsNCT04671303 2025-05-11
To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06585644 2024-09-05
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting